04.22.15
The U.S. Food and Drug Administration (FDA) has approved an updated version of Dune Medical Devices' flagship product, MarginProbe, a device that enables real-time detection of cancer at the surface of excised tissue specimens during breast-conserving surgery.
Surgeon feedback, innovative design ideas, and miniaturization engineering were the driving forces behind the development of MarginProbe 1.2, according to the company. This new version, which utilizes the same FDA-approved, diagnostic technology as version 1.1, is focused on improving functionality, portability, and overall ease of use.
"Our goal in offering this update is to provide surgeons with the most effective, easy-to-use product when they walk into a lumpectomy case," said Dan Hashimshony, CEO of Dune Medical Devices. "Once the MarginProbe demonstrated national success across all territories, we began enhancing the usability for surgeons while offering simpler handling. Despite the fact that we offer the only product dedicated to the need for intraoperative margin assessment in breast cancer surgery, we always knew it's critical we constantly listen to our customer base and do our best to offer them further innovation."
Feature enhancements for MarginProbe 1.2 include:
Dune Medical Devices, whose global headquarters is in Israel, provides proprietary tissue characterization technology for the identification of cancerous tissue. The privately held company hopes to eventually apply its technology to a broader range of surgical and diagnostic applications.
Surgeon feedback, innovative design ideas, and miniaturization engineering were the driving forces behind the development of MarginProbe 1.2, according to the company. This new version, which utilizes the same FDA-approved, diagnostic technology as version 1.1, is focused on improving functionality, portability, and overall ease of use.
"Our goal in offering this update is to provide surgeons with the most effective, easy-to-use product when they walk into a lumpectomy case," said Dan Hashimshony, CEO of Dune Medical Devices. "Once the MarginProbe demonstrated national success across all territories, we began enhancing the usability for surgeons while offering simpler handling. Despite the fact that we offer the only product dedicated to the need for intraoperative margin assessment in breast cancer surgery, we always knew it's critical we constantly listen to our customer base and do our best to offer them further innovation."
Feature enhancements for MarginProbe 1.2 include:
- Reduced size and weight: A major highlight of MarginProbe 1.2 is the reduced size. The new unit is in tabletop form (29 x 43 x 38 centimeters in size) and weighs 35 pounds, making it 75 percent lighter and considerably easier to handle in busy operating rooms.
- A brighter screen: The screen's brightness has been enhanced to provide surgeons a clearer screen image.
- Wider viewing angle: With MarginProbe 1.2, surgeons clearly view the screen from anywhere in the operating room without encountering a glare, pixilation, or a blind spot.
- Improved on-screen notices: Ensuring key alerts are easier to notice in the OR ambiance.
- Startup Time Reduced by 50: The startup time for MarginProbe 1.2 is reduced from approximately three minutes to 90 seconds.
- Improved service time: Due to its new reduced size, technicians are able to provide faster service, reducing down time in case service is needed.
Dune Medical Devices, whose global headquarters is in Israel, provides proprietary tissue characterization technology for the identification of cancerous tissue. The privately held company hopes to eventually apply its technology to a broader range of surgical and diagnostic applications.